TISIDB

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Single-pass type IV membrane protein Cell junction, synapse, synaptosome Cell membrane Note=Colocalizes with KCNB1 at the cell membrane. ; SUBCELLULAR LOCATION: Isoform 2: Secreted
Domain	PF05739 SNARE domain PF00804 Syntaxin
Function	Plays a role in hormone and neurotransmitter exocytosis (By similarity). Potentially involved in docking of synaptic vesicles at presynaptic active zones. May mediate Ca(2+)-regulation of exocytosis acrosomal reaction in sperm.

> Gene Ontology [ TOP ]
Biological Process	GO:0001505 regulation of neurotransmitter levels GO:0001956 positive regulation of neurotransmitter secretion GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0006820 anion transport GO:0006835 dicarboxylic acid transport GO:0006836 neurotransmitter transport GO:0006887 exocytosis GO:0006904 vesicle docking involved in exocytosis GO:0006906 vesicle fusion GO:0007269 neurotransmitter secretion GO:0009306 protein secretion GO:0009629 response to gravity GO:0009914 hormone transport GO:0010701 positive regulation of norepinephrine secretion GO:0010807 regulation of synaptic vesicle priming GO:0010817 regulation of hormone levels GO:0014047 glutamate secretion GO:0014061 regulation of norepinephrine secretion GO:0015711 organic anion transport GO:0015833 peptide transport GO:0015837 amine transport GO:0015844 monoamine transport GO:0015850 organic hydroxy compound transport GO:0015874 norepinephrine transport GO:0016050 vesicle organization GO:0016079 synaptic vesicle exocytosis GO:0016081 synaptic vesicle docking GO:0016082 synaptic vesicle priming GO:0017156 calcium ion regulated exocytosis GO:0017157 regulation of exocytosis GO:0017158 regulation of calcium ion-dependent exocytosis GO:0022406 membrane docking GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030073 insulin secretion GO:0031629 synaptic vesicle fusion to presynaptic active zone membrane GO:0033605 positive regulation of catecholamine secretion GO:0042391 regulation of membrane potential GO:0042886 amide transport GO:0043254 regulation of protein complex assembly GO:0044801 single-organism membrane fusion GO:0045026 plasma membrane fusion GO:0045055 regulated exocytosis GO:0045921 positive regulation of exocytosis GO:0045956 positive regulation of calcium ion-dependent exocytosis GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0046928 regulation of neurotransmitter secretion GO:0046942 carboxylic acid transport GO:0048243 norepinephrine secretion GO:0048278 vesicle docking GO:0048284 organelle fusion GO:0048489 synaptic vesicle transport GO:0050432 catecholamine secretion GO:0050433 regulation of catecholamine secretion GO:0050708 regulation of protein secretion GO:0050796 regulation of insulin secretion GO:0050804 modulation of synaptic transmission GO:0050806 positive regulation of synaptic transmission GO:0051047 positive regulation of secretion GO:0051588 regulation of neurotransmitter transport GO:0051590 positive regulation of neurotransmitter transport GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0051937 catecholamine transport GO:0051952 regulation of amine transport GO:0051954 positive regulation of amine transport GO:0060078 regulation of postsynaptic membrane potential GO:0060079 excitatory postsynaptic potential GO:0060627 regulation of vesicle-mediated transport GO:0061025 membrane fusion GO:0090087 regulation of peptide transport GO:0090174 organelle membrane fusion GO:0090276 regulation of peptide hormone secretion GO:0097479 synaptic vesicle localization GO:0097480 establishment of synaptic vesicle localization GO:0098815 modulation of excitatory postsynaptic potential GO:0099003 vesicle-mediated transport in synapse GO:0099500 vesicle fusion to plasma membrane GO:0099504 synaptic vesicle cycle GO:0099531 presynaptic process involved in chemical synaptic transmission GO:0099565 chemical synaptic transmission, postsynaptic GO:0099643 signal release from synapse GO:1902803 regulation of synaptic vesicle transport GO:1903305 regulation of regulated secretory pathway GO:1903307 positive regulation of regulated secretory pathway GO:1903532 positive regulation of secretion by cell GO:2000300 regulation of synaptic vesicle exocytosis GO:2000463 positive regulation of excitatory postsynaptic potential
Molecular Function	GO:0000149 SNARE binding GO:0001948 glycoprotein binding GO:0005246 calcium channel regulator activity GO:0005484 SNAP receptor activity GO:0008200 ion channel inhibitor activity GO:0016247 channel regulator activity GO:0016248 channel inhibitor activity GO:0017022 myosin binding GO:0017081 chloride channel regulator activity GO:0019855 calcium channel inhibitor activity GO:0019869 chloride channel inhibitor activity GO:0030674 protein binding, bridging GO:0032028 myosin head/neck binding GO:0032036 myosin heavy chain binding GO:0043008 ATP-dependent protein binding GO:0044325 ion channel binding GO:0046982 protein heterodimerization activity GO:0047485 protein N-terminus binding GO:0048306 calcium-dependent protein binding GO:0060090 binding, bridging
Cellular Component	GO:0008021 synaptic vesicle GO:0008076 voltage-gated potassium channel complex GO:0015629 actin cytoskeleton GO:0030133 transport vesicle GO:0030141 secretory granule GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030672 synaptic vesicle membrane GO:0031201 SNARE complex GO:0034702 ion channel complex GO:0034703 cation channel complex GO:0034705 potassium channel complex GO:0042641 actomyosin GO:0070032 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070033 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex GO:0070044 synaptobrevin 2-SNAP-25-syntaxin-1a complex GO:0070382 exocytic vesicle GO:0098793 presynapse GO:0099501 exocytic vesicle membrane GO:0099503 secretory vesicle GO:1902495 transmembrane transporter complex GO:1990351 transporter complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04130 SNARE interactions in vesicular transport hsa04721 Synaptic vesicle cycle hsa04911 Insulin secretion
Reactome	R-HSA-264642: Acetylcholine Neurotransmitter Release Cycle R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-212676: Dopamine Neurotransmitter Release Cycle R-HSA-888590: GABA synthesis, release, reuptake and degradation R-HSA-210500: Glutamate Neurotransmitter Release Cycle R-HSA-168256: Immune System R-HSA-5663205: Infectious disease R-HSA-264876: Insulin processing R-HSA-163685: Integration of energy metabolism R-HSA-6794361: Interactions of neurexins and neuroligins at synapses R-HSA-5682910: LGI-ADAM interactions R-HSA-1430728: Metabolism R-HSA-392499: Metabolism of proteins R-HSA-112316: Neuronal System R-HSA-168799: Neurotoxicity of clostridium toxins R-HSA-112310: Neurotransmitter Release Cycle R-HSA-181430: Norepinephrine Neurotransmitter Release Cycle R-HSA-2980736: Peptide hormone metabolism R-HSA-6794362: Protein-protein interactions at synapses R-HSA-422356: Regulation of insulin secretion R-HSA-181429: Serotonin Neurotransmitter Release Cycle R-HSA-449147: Signaling by Interleukins R-HSA-5250971: Toxicity of botulinum toxin type C (BoNT/C) R-HSA-112315: Transmission across Chemical Synapses R-HSA-5339562: Uptake and actions of bacterial toxins

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04130 SNARE interactions in vesicular transport
hsa04721 Synaptic vesicle cycle
hsa04911 Insulin secretion

Reactome

R-HSA-264642: Acetylcholine Neurotransmitter Release Cycle
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-212676: Dopamine Neurotransmitter Release Cycle
R-HSA-888590: GABA synthesis, release, reuptake and degradation
R-HSA-210500: Glutamate Neurotransmitter Release Cycle
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-264876: Insulin processing
R-HSA-163685: Integration of energy metabolism
R-HSA-6794361: Interactions of neurexins and neuroligins at synapses
R-HSA-5682910: LGI-ADAM interactions
R-HSA-1430728: Metabolism
R-HSA-392499: Metabolism of proteins
R-HSA-112316: Neuronal System
R-HSA-168799: Neurotoxicity of clostridium toxins
R-HSA-112310: Neurotransmitter Release Cycle
R-HSA-181430: Norepinephrine Neurotransmitter Release Cycle
R-HSA-2980736: Peptide hormone metabolism
R-HSA-6794362: Protein-protein interactions at synapses
R-HSA-422356: Regulation of insulin secretion
R-HSA-181429: Serotonin Neurotransmitter Release Cycle
R-HSA-449147: Signaling by Interleukins
R-HSA-5250971: Toxicity of botulinum toxin type C (BoNT/C)
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-5339562: Uptake and actions of bacterial toxins

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between STX1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of STX1A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of STX1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.952	0.0344
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.971	0.415
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.936	0.293
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.346	0.593
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.021	0.988
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.821	0.68
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.145	0.688
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.457	0.515
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.303	0.655
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.564	0.589
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.685	0.614
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.024	0.844

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of STX1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STX1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STX1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STX1A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STX1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of STX1A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between STX1A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	STX1A
Name	syntaxin 1A (brain)
Aliases	HPC-1; p35-1; STX1; SYN1A; neuron-specific antigen HPC-1; Syntaxin-1A
Chromosomal Location	7q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting STX1A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse STX1A